Highlights Altimmune, Inc.

Equities

ALT

US02155H2004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
7.27 ^USD	-1.22%		+10.99%	-35.38%

Apr. 30	North American Morning Briefing : More Earnings -2-	DJ
Apr. 29	Altimmune Shares Decline After Guggenheim Downgrade	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : More Earnings -2-	Apr. 30	DJ
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B	Mar. 27	MT
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q4 Revenue $37,000	Mar. 27	MT
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Zealand shares surge on liver drug data from Boehringer pact	Feb. 26	RE
Altimmune shares slide after Kerrisdale Capital takes short position	Feb. 13	RE
Weight loss drug windfall attracts pharma companies	Jan. 11	RE
Drugmakers plot way into obesity market with deals and development	Jan. 11	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04	RE
Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide	Nov. 30	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q3 Revenue $362,000	Nov. 07	MT
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Altimmune Gets FDA Fast Track Label for Pemvidutide to Treat Non-Alcoholic Steatohepatitis	23-10-26	MT
Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis	23-10-26	CI
Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q2 Revenue $6,000	23-08-10	MT
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial data	23-08-08	RE
Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis	23-08-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Altimmune, Inc.

Equities

ALT

US02155H2004

Highlights

Filters